Literature DB >> 14627817

High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity.

Lars Borrmann1, Ralf Schwanbeck, Tomasz Heyduk, Birte Seebeck, Piere Rogalla, Jörn Bullerdiek, Jacek R Wisniewski.   

Abstract

High mobility group A2 (HMGA2) chromosomal non-histone protein and its derivatives play an important role in development and progression of benign and malignant tumors, obesity and arteriosclerosis, although the underlying mechanisms of these conditions are poorly understood. Therefore, we tried to identify target genes for this transcriptional regulator and to provide insights in the mechanism of interaction to its target. Multiple genes have been identified by microarray experiments as being transcriptionally regulated by HMGA2. Among these we chose the ERCC1 gene, encoding a DNA repair protein, for this study. DNA-binding studies were performed using HMGA2 and C-terminally truncated DeltaHMGA2, a derivative that is frequently observed in a variety of tumors. A unique high affinity HMGA2 binding site was mapped to a specific AT-rich region located -323 to -298 upstream of the ERCC1 transcription start site, distinguishing it from other potential AT-rich binding sites. The observed 1:1 stoichiometry for the binding of wild-type HMGA2 to this region was altered to 1:2 upon binding of truncated DeltaHMGA2, causing DNA bending. Furthermore, the regulatory effect of HMGA2 was confirmed by luciferase promoter assays showing that ERCC1 promoter activity is down-regulated by all investigated HMGA2 forms, with the most striking effect exerted by DeltaHMGA2. Our results provide the first insights into how HMGA2 and its aberrant forms bind and regulate the ERCC1 promoter.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627817      PMCID: PMC290254          DOI: 10.1093/nar/gkg884

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  58 in total

1.  Architecture of high mobility group protein I-C.DNA complex and its perturbation upon phosphorylation by Cdc2 kinase.

Authors:  R Schwanbeck; G Manfioletti; J R Wiśniewski
Journal:  J Biol Chem       Date:  2000-01-21       Impact factor: 5.157

2.  High level expression of the HMGI (Y) gene during embryonic development.

Authors:  G Chiappetta; V Avantaggiato; R Visconti; M Fedele; S Battista; F Trapasso; B M Merciai; V Fidanza; V Giancotti; M Santoro; A Simeone; A Fusco
Journal:  Oncogene       Date:  1996-12-05       Impact factor: 9.867

3.  Ten pulmonary chondroid hamartomas with chromosome 6p21 breakpoints within the HMG-I(Y) gene or its immediate surroundings.

Authors:  B Kazmierczak; S Wanschura; B Rommel; S Bartnitzke; J Bullerdiek
Journal:  J Natl Cancer Inst       Date:  1996-09-04       Impact factor: 13.506

4.  Structural and functional consequences of mutations within the hydrophobic cores of the HMG1-box domain of the Chironomus high-mobility-group protein 1a.

Authors:  J R Wísniewski; K Hessler; P Claus; K Zechel
Journal:  Eur J Biochem       Date:  1997-01-15

5.  Thiol-reactive, luminescent Europium chelates: luminescence probes for resonance energy transfer distance measurements in biomolecules.

Authors:  E Heyduk; T Heyduk
Journal:  Anal Biochem       Date:  1997-06-01       Impact factor: 3.365

6.  Molecular characterization of a complex chromosomal rearrangement in a pleomorphic salivary gland adenoma involving the 3'-UTR of HMGIC.

Authors:  J M Geurts; E F Schoenmakers; W J Van de Ven
Journal:  Cancer Genet Cytogenet       Date:  1997-06

7.  LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family.

Authors:  M M Petit; R Mols; E F Schoenmakers; N Mandahl; W J Van de Ven
Journal:  Genomics       Date:  1996-08-15       Impact factor: 5.736

8.  Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease.

Authors:  A M Sijbers; W L de Laat; R R Ariza; M Biggerstaff; Y F Wei; J G Moggs; K C Carter; B K Shell; E Evans; M C de Jong; S Rademakers; J de Rooij; N G Jaspers; J H Hoeijmakers; R D Wood
Journal:  Cell       Date:  1996-09-06       Impact factor: 41.582

9.  Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct.

Authors:  J G Moggs; K J Yarema; J M Essigmann; R D Wood
Journal:  J Biol Chem       Date:  1996-03-22       Impact factor: 5.157

10.  A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization.

Authors:  Y Tamimi; H G van der Poel; H F Karthaus; F M Debruyne; J A Schalken
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

View more
  15 in total

1.  miR-16 regulates proliferation and apoptosis of pituitary adenoma cells by inhibiting HMGA2.

Authors:  Yingying Niu; Hongbo Zhou; Yancui Liu; Yunfeng Wang; Jinding Xie; Chong Feng; Ning An
Journal:  Oncol Lett       Date:  2018-12-28       Impact factor: 2.967

Review 2.  Critical role of HMGA proteins in cancer cell chemoresistance.

Authors:  Daniela D'Angelo; Paula Mussnich; Claudio Arra; Sabrina Battista; Alfredo Fusco
Journal:  J Mol Med (Berl)       Date:  2017-03-14       Impact factor: 4.599

3.  Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.

Authors:  Surabhi Dangi-Garimella; Seth B Krantz; Morgan R Barron; Mario A Shields; Michael J Heiferman; Paul J Grippo; David J Bentrem; Hidayatullah G Munshi
Journal:  Cancer Res       Date:  2010-12-08       Impact factor: 12.701

4.  Epigenetic reduction of DNA repair in progression to gastrointestinal cancer.

Authors:  Carol Bernstein; Harris Bernstein
Journal:  World J Gastrointest Oncol       Date:  2015-05-15

Review 5.  HMGA2 and high-grade serous ovarian carcinoma.

Authors:  Jingjing Wu; Jian-Jun Wei
Journal:  J Mol Med (Berl)       Date:  2013-05-19       Impact factor: 4.599

6.  Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis.

Authors:  Leon Raskin; Douglas R Fullen; Thomas J Giordano; Dafydd G Thomas; Marcus L Frohm; Kelly B Cha; Jaeil Ahn; Bhramar Mukherjee; Timothy M Johnson; Stephen B Gruber
Journal:  J Invest Dermatol       Date:  2013-04-30       Impact factor: 8.551

7.  HMGA2 Expression in Renal Carcinoma and its Clinical Significance.

Authors:  Ying Liu; Qi-Zhong Fu; Lin Pu; Qing-Guo Meng; Xian-Feng Liu; Sheng-Fang Dong; Jian-Xun Yang; Guang-Yao Lv
Journal:  J Med Biochem       Date:  2015-07-14       Impact factor: 3.402

8.  The Architectural Chromatin Factor High Mobility Group A1 Enhances DNA Ligase IV Activity Influencing DNA Repair.

Authors:  Ilenia Pellarin; Laura Arnoldo; Silvia Costantini; Silvia Pegoraro; Gloria Ros; Carlotta Penzo; Gianluca Triolo; Francesca Demarchi; Riccardo Sgarra; Alessandro Vindigni; Guidalberto Manfioletti
Journal:  PLoS One       Date:  2016-10-10       Impact factor: 3.240

9.  TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.

Authors:  Cai M Roberts; Michelle A Tran; Mary C Pitruzzello; Wei Wen; Joana Loeza; Thanh H Dellinger; Gil Mor; Carlotta A Glackin
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

10.  HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy.

Authors:  Heike Summer; Ou Li; Qiuye Bao; Lihong Zhan; Sabrina Peter; Padmapriya Sathiyanathan; Dana Henderson; Thomas Klonisch; Steven D Goodman; Peter Dröge
Journal:  Nucleic Acids Res       Date:  2009-05-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.